SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2013 Customer	Jun. 30, 2012	Mar. 31, 2012 Payment	Jun. 30, 2013 Quarter Customer	Jun. 30, 2012	Jun. 28, 2013	Dec. 31, 2012
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	$ 3,903,942			$ 3,903,942			$ 5,082,360
Number of customers	2			2
Royalty revenue	3,197,603	2,491,313		6,630,503	4,391,282
Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]
Number of quarters after which revenue is recognized (in quarters)				1
Number of days after calendar year, after which payments and report are received				90 days
Number of years for which bad debt expense not recorded				3 years
Allowance for doubtful accounts	30,000	30,000		30,000	30,000
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs	30,000			30,000
Royalty Buy-Down [Abstract]
Initial payment for royalty buy down			1,500,000	0	1,500,000
Number of additional cash payments for royalty buy down			5
Deferred royalty buy-down	2,750,000			2,750,000			2,750,000
Deferred costs, amortization period				5 years
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock granted during period, value of stock options	79,000
Expected volatility rate				37.00%
Risk free interest rate				0.68%
Average exercise period				5 years
Stock-based compensation expense	79,049	135,879		105,449	175,685
Total number of shares
Outstanding, beginning of period (in shares)				1,182,000
Granted (in shares)				15,000
Forfeited (in shares)				0
Exercised (in shares)				0
Expired (in shares)				0
Outstanding, end of period (in shares)	1,197,000			1,197,000
Exercisable, end of period (in shares)	1,177,000			1,177,000
Weighted-Average Exercise Price
Outstanding, beginning of period (in dollars per share)				$ 8.90
Granted (in dollars per share)				$ 15.85
Forfeited (in dollars per share)				$ 0
Exercised (in dollars per share)				$ 0
Expired (in dollars per share)				$ 0
Outstanding, end of period (in dollars per share)	$ 8.99			$ 8.99
Exercisable, end of period (in dollars per share)	$ 8.64			$ 8.64
Proceeds from stock option exercises				0	78,000
Aggregate intrinsic value of options outstanding and exercisable	8,200,000			8,200,000
Closing price of Company stock (in dollars per share)						$ 15.60
Unrecognized compensation cost related to non-vested stock options outstanding	0			0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				10 years
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	79,049	122,679		92,249	144,817
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	13,200		13,200	30,868
Auxilium [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	1,400,000			1,400,000
Royalty revenue	4,700,000
Deferred revenue	500,000			500,000
Auxilium [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				36.00%
Auxilium [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	65.00%
DFB Biotech Inc. [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	2,500,000			2,500,000
Royalty revenue	$ 2,500,000
DFB Biotech Inc. [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				64.00%
DFB Biotech Inc. [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	35.00%